Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Walmsley

Showing results (171-180 of 199) with videos related to

Pageof 20
Sort By:
Patient Preference and Adherence|December 20, 2022
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286)Marina B Klein, Jim Young, David Ortiz-Paredes, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Vaccine|July 2, 2025
COVID-19 vaccine uptake in a retrospective population-based cohort of people living with and without HIV in Ontario, CanadaCassandra Freitas, Curtis L Cooper, Abigail E Kroch, et al.
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Gastro Hep Advances|May 25, 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated With Impaired Health-Related Quality of Life in People With HIVFelice Cinque, Michael Nudo, Sahar Saeed, et al.
AIDS Research and Human Retroviruses|August 3, 2019
Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and AgingErin E Sundermann, Kristine M Erlandson, Caitlin N Pope, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2021
Routinized Syphilis Screening Among Men Living With Human Immunodeficiency Virus: A Stepped Wedge Cluster Randomized Controlled TrialAnn N Burchell, Darrell H S Tan, Ramandip Grewal, et al.
BMJ Open|December 17, 2021
CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort studyCecilia T Costiniuk, Joel Singer, Marc-André Langlois, et al.
BMC Infectious Diseases|September 13, 2017
The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocolMadeleine Durand, Carl Chartrand-Lefebvre, Jean-Guy Baril, et al.
Med (New York, N.Y.)|April 19, 2022
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variantsArinjay Banerjee, Jocelyne Lew, Andrea Kroeker, et al.
Pageof 20

Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
Patient Preference and Adherence|December 20, 2022
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286)Marina B Klein, Jim Young, David Ortiz-Paredes, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Vaccine|July 2, 2025
COVID-19 vaccine uptake in a retrospective population-based cohort of people living with and without HIV in Ontario, CanadaCassandra Freitas, Curtis L Cooper, Abigail E Kroch, et al.
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Gastro Hep Advances|May 25, 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated With Impaired Health-Related Quality of Life in People With HIVFelice Cinque, Michael Nudo, Sahar Saeed, et al.
AIDS Research and Human Retroviruses|August 3, 2019
Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and AgingErin E Sundermann, Kristine M Erlandson, Caitlin N Pope, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2021
Routinized Syphilis Screening Among Men Living With Human Immunodeficiency Virus: A Stepped Wedge Cluster Randomized Controlled TrialAnn N Burchell, Darrell H S Tan, Ramandip Grewal, et al.
BMJ Open|December 17, 2021
CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort studyCecilia T Costiniuk, Joel Singer, Marc-André Langlois, et al.
BMC Infectious Diseases|September 13, 2017
The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocolMadeleine Durand, Carl Chartrand-Lefebvre, Jean-Guy Baril, et al.
Med (New York, N.Y.)|April 19, 2022
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variantsArinjay Banerjee, Jocelyne Lew, Andrea Kroeker, et al.
Pageof 20